Thermo Fisher Scientific Inc. (NYSE:TMO) Position Boosted by Vise Technologies Inc.

Vise Technologies Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 140.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,170 shares of the medical research company's stock after buying an additional 2,439 shares during the period. Vise Technologies Inc.'s holdings in Thermo Fisher Scientific were worth $2,169,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $253,000. Intact Investment Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $1,121,000. Fifth Third Bancorp raised its holdings in shares of Thermo Fisher Scientific by 11.6% in the 4th quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock valued at $174,305,000 after buying an additional 34,917 shares during the period. Finally, Independence Bank of Kentucky increased its holdings in Thermo Fisher Scientific by 21.0% during the 4th quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock worth $1,990,000 after purchasing an additional 663 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. UBS Group dropped their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Finally, Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $607.43.

Thermo Fisher Scientific Stock Up 0.3%

Shares of TMO traded up $1.02 during midday trading on Thursday, reaching $403.15. 1,061,739 shares of the company were exchanged, compared to its average volume of 2,313,305. The stock has a 50-day moving average price of $435.42 and a 200-day moving average price of $502.00. The company has a market cap of $152.19 billion, a price-to-earnings ratio of 24.39, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1-year low of $390.49 and a 1-year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.11 earnings per share. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.